{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:33:36Z","timestamp":1758040416398,"version":"3.44.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.amjmed.2004.10.003","type":"journal-article","created":{"date-parts":[[2005,1,4]],"date-time":"2005-01-04T07:16:50Z","timestamp":1104823010000},"page":"972-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin"],"prefix":"10.1016","volume":"117","author":[{"given":"Lawrence","family":"Rice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2004.10.003_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2004.10.003_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107602969700300406","article-title":"Efficacy of danazol with autoimmune thrombocytopenia","volume":"3","author":"Kim","year":"1997","journal-title":"Clin Appl Thrombosis\/Hemostasis"},{"key":"10.1016\/j.amjmed.2004.10.003_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/stem.5530160719","article-title":"Endogenous (e)TPO levels in health and disease: possible clues for therapeutic intervention. Thrombopoietin","volume":"16","author":"Nichol","year":"1998","journal-title":"Stem Cells"},{"key":"10.1016\/j.amjmed.2004.10.003_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ajh.1181","article-title":"Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy","volume":"68","author":"Rice","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjmed.2004.10.003_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.10209","article-title":"Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome","volume":"71","author":"Chan","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjmed.2004.10.003_bib6","first-page":"86a","article-title":"An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura (ITP)","volume":"102","author":"Bussel","year":"2003","journal-title":"Blood"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304006266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304006266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:33:21Z","timestamp":1757579601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934304006266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0002934304006266"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.10.003","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}